Ethanol consumption during pregnancy can have lifelong consequences for the offspring, their family and society. Fetal alcohol spectrum disorders (FASD) include a range of physical and behavioral effects with the most significant impact occurring as a result of the effects of ethanol on the developing central nervous system (CNS). To date, there are no FDA approved drugs that have been tested that prevent/reduce or specifically treat the symptoms of FASD. There are several promising lines of research from rodent models aimed at reducing the neurotoxic effects of ethanol on the developing CNS or in treating the resulting behavioral impairments but these have not yet moved to clinical testing. The current review discusses some of the most promising targets for intervention and provides a review of the past and ongoing efforts to develop and screen pharmacological treatments for reducing the effects of prenatal ethanol exposure.
|Title of host publication||International Review of Neurobiology|
|Number of pages||18|
|State||Published - 2016|
|Name||International Review of Neurobiology|
Bibliographical noteFunding Information:
This work was funded, in part, by SBIR AA021038 and a NIAAA contract to JML and a Research Grant from the Vice President for Research at University of Kentucky to SB.
© 2016 Elsevier Inc.
- Fetal alcohol spectrum disorders
- Novel flavonoids
- Polyamine modulators
- Rodent models
- α7 Agonists
ASJC Scopus subject areas
- Clinical Neurology
- Cellular and Molecular Neuroscience